A study protocol for the cardiac effects of a single dose of either oxytocin 2.5 IU or carbetocin 100 µg after caesarean delivery: a prospective randomized controlled multi-centre trial in Norway [version 1; peer review: 2 approved]

Background: Both oxytocin and carbetocin are used to prevent uterine atony and post-partum haemorrhage after caesarean delivery in many countries, including Norway. Oxytocin causes dose-dependent ST-depression, troponin release, prolongation of QT-time and arrythmia, but little is known about myocar...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maria Bekkenes, Marte Morin Jørgensen, Anne Flem Jacobsen, Morten Wang Fagerland, Helene Rakstad-Larsen, Ole Geir Solberg, Lars Aaberge, Olav Klingenberg, Trude Steinsvik, Leiv Arne Rosseland
Formato:	article
Lenguaje:	EN
Publicado:	F1000 Research Ltd 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b8a79d929e3149e093132bb3a3af4a80
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b8a79d929e3149e093132bb3a3af4a80
record_format	dspace
spelling	oai:doaj.org-article:b8a79d929e3149e093132bb3a3af4a802021-11-08T10:53:48ZA study protocol for the cardiac effects of a single dose of either oxytocin 2.5 IU or carbetocin 100 µg after caesarean delivery: a prospective randomized controlled multi-centre trial in Norway [version 1; peer review: 2 approved]2046-140210.12688/f1000research.73112.1https://doaj.org/article/b8a79d929e3149e093132bb3a3af4a802021-09-01T00:00:00Zhttps://f1000research.com/articles/10-973/v1https://doaj.org/toc/2046-1402Background: Both oxytocin and carbetocin are used to prevent uterine atony and post-partum haemorrhage after caesarean delivery in many countries, including Norway. Oxytocin causes dose-dependent ST-depression, troponin release, prolongation of QT-time and arrythmia, but little is known about myocardial effects of carbetocin. We have previously demonstrated comparable vasodilatory effects of oxytocin and carbetocin and are now undertaking a Phase 4 trial to investigate whether carbetocin causes similar changes to myocardial markers compared with oxytocin. Methods: Our randomized controlled trial will be conducted at three obstetrics units at Oslo University Hospital and Akershus University Hospital, Norway. Planned enrolment will be of 240 healthy, singleton pregnant women aged 18 to 50 years undergoing planned caesarean delivery. Based on pilot study data, each participant will receive a one-minute intravenous injection of either oxytocin 2.5 IU or carbetocin 100 µg during caesarean delivery. The prespecified primary outcome is the change from baseline in high-sensitive troponin I plasma concentrations at 6–10 hours after study drug administration. Secondary outcomes include uterine tone grade at 2.5 and five minutes after study drug administration, adverse events for up to 48 hours after study drug administration, estimated blood loss within eight hours of delivery, need for rescue treatment and direct/indirect costs. Enrolment and primary analysis are expected to be completed by the end of 2021. Discussion: Women undergoing caesarean delivery should be assessed for cardiovascular risk particularly as women with an obstetric history of pregnancy induced hypertension, gestational diabetes mellitus, preterm birth, placental abruption, and stillbirth are at increased risk of future cardiovascular disease. Any additional ischaemic myocardial risk from uterotonic agents will need to be balanced with the benefit of reducing the risk of postpartum haemorrhage. Any potential cardiotoxicity difference between oxytocin and carbetocin will help inform treatment decisions for pregnant women. Registration: Clinicaltrials.gov NCT03899961 (02/04/2019).Maria BekkenesMarte Morin JørgensenAnne Flem JacobsenMorten Wang FagerlandHelene Rakstad-LarsenOle Geir SolbergLars AabergeOlav KlingenbergTrude SteinsvikLeiv Arne RosselandF1000 Research LtdarticleMedicineRScienceQENF1000Research, Vol 10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Maria Bekkenes Marte Morin Jørgensen Anne Flem Jacobsen Morten Wang Fagerland Helene Rakstad-Larsen Ole Geir Solberg Lars Aaberge Olav Klingenberg Trude Steinsvik Leiv Arne Rosseland A study protocol for the cardiac effects of a single dose of either oxytocin 2.5 IU or carbetocin 100 µg after caesarean delivery: a prospective randomized controlled multi-centre trial in Norway [version 1; peer review: 2 approved]
description	Background: Both oxytocin and carbetocin are used to prevent uterine atony and post-partum haemorrhage after caesarean delivery in many countries, including Norway. Oxytocin causes dose-dependent ST-depression, troponin release, prolongation of QT-time and arrythmia, but little is known about myocardial effects of carbetocin. We have previously demonstrated comparable vasodilatory effects of oxytocin and carbetocin and are now undertaking a Phase 4 trial to investigate whether carbetocin causes similar changes to myocardial markers compared with oxytocin. Methods: Our randomized controlled trial will be conducted at three obstetrics units at Oslo University Hospital and Akershus University Hospital, Norway. Planned enrolment will be of 240 healthy, singleton pregnant women aged 18 to 50 years undergoing planned caesarean delivery. Based on pilot study data, each participant will receive a one-minute intravenous injection of either oxytocin 2.5 IU or carbetocin 100 µg during caesarean delivery. The prespecified primary outcome is the change from baseline in high-sensitive troponin I plasma concentrations at 6–10 hours after study drug administration. Secondary outcomes include uterine tone grade at 2.5 and five minutes after study drug administration, adverse events for up to 48 hours after study drug administration, estimated blood loss within eight hours of delivery, need for rescue treatment and direct/indirect costs. Enrolment and primary analysis are expected to be completed by the end of 2021. Discussion: Women undergoing caesarean delivery should be assessed for cardiovascular risk particularly as women with an obstetric history of pregnancy induced hypertension, gestational diabetes mellitus, preterm birth, placental abruption, and stillbirth are at increased risk of future cardiovascular disease. Any additional ischaemic myocardial risk from uterotonic agents will need to be balanced with the benefit of reducing the risk of postpartum haemorrhage. Any potential cardiotoxicity difference between oxytocin and carbetocin will help inform treatment decisions for pregnant women. Registration: Clinicaltrials.gov NCT03899961 (02/04/2019).
format	article
author	Maria Bekkenes Marte Morin Jørgensen Anne Flem Jacobsen Morten Wang Fagerland Helene Rakstad-Larsen Ole Geir Solberg Lars Aaberge Olav Klingenberg Trude Steinsvik Leiv Arne Rosseland
author_facet	Maria Bekkenes Marte Morin Jørgensen Anne Flem Jacobsen Morten Wang Fagerland Helene Rakstad-Larsen Ole Geir Solberg Lars Aaberge Olav Klingenberg Trude Steinsvik Leiv Arne Rosseland
author_sort	Maria Bekkenes
title	A study protocol for the cardiac effects of a single dose of either oxytocin 2.5 IU or carbetocin 100 µg after caesarean delivery: a prospective randomized controlled multi-centre trial in Norway [version 1; peer review: 2 approved]
title_short	A study protocol for the cardiac effects of a single dose of either oxytocin 2.5 IU or carbetocin 100 µg after caesarean delivery: a prospective randomized controlled multi-centre trial in Norway [version 1; peer review: 2 approved]
title_full	A study protocol for the cardiac effects of a single dose of either oxytocin 2.5 IU or carbetocin 100 µg after caesarean delivery: a prospective randomized controlled multi-centre trial in Norway [version 1; peer review: 2 approved]
title_fullStr	A study protocol for the cardiac effects of a single dose of either oxytocin 2.5 IU or carbetocin 100 µg after caesarean delivery: a prospective randomized controlled multi-centre trial in Norway [version 1; peer review: 2 approved]
title_full_unstemmed	A study protocol for the cardiac effects of a single dose of either oxytocin 2.5 IU or carbetocin 100 µg after caesarean delivery: a prospective randomized controlled multi-centre trial in Norway [version 1; peer review: 2 approved]
title_sort	study protocol for the cardiac effects of a single dose of either oxytocin 2.5 iu or carbetocin 100 µg after caesarean delivery: a prospective randomized controlled multi-centre trial in norway [version 1; peer review: 2 approved]
publisher	F1000 Research Ltd
publishDate	2021
url	https://doaj.org/article/b8a79d929e3149e093132bb3a3af4a80
work_keys_str_mv	AT mariabekkenes astudyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved AT martemorinjørgensen astudyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved AT anneflemjacobsen astudyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved AT mortenwangfagerland astudyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved AT helenerakstadlarsen astudyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved AT olegeirsolberg astudyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved AT larsaaberge astudyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved AT olavklingenberg astudyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved AT trudesteinsvik astudyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved AT leivarnerosseland astudyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved AT mariabekkenes studyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved AT martemorinjørgensen studyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved AT anneflemjacobsen studyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved AT mortenwangfagerland studyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved AT helenerakstadlarsen studyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved AT olegeirsolberg studyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved AT larsaaberge studyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved AT olavklingenberg studyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved AT trudesteinsvik studyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved AT leivarnerosseland studyprotocolforthecardiaceffectsofasingledoseofeitheroxytocin25iuorcarbetocin100μgaftercaesareandeliveryaprospectiverandomizedcontrolledmulticentretrialinnorwayversion1peerreview2approved
_version_	1718442561100578816

A study protocol for the cardiac effects of a single dose of either oxytocin 2.5 IU or carbetocin 100 µg after caesarean delivery: a prospective randomized controlled multi-centre trial in Norway [version 1; peer review: 2 approved]

Ejemplares similares